The efficacy of interferon-alpha treatment in human T-lymphotropic virus type-I-associated myelopathy

Jpn J Med. 1990 Jul-Aug;29(4):362-7. doi: 10.2169/internalmedicine1962.29.362.

Abstract

We investigated the efficacy of interferon-alpha (IFN-alpha) treatment in 5 patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM). Treatment with IFN-alpha yielded clinical improvement of gait, and sensory and/or sphincter disturbance in 4 out of the 5 HAM patients. IFN-alpha treatment did not bring about uniform changes in lymphocyte subsets or anti-HTLV-I antibody titer of peripheral blood. Although the stimulation indexes to phytohemagglutinin, concanavalin A, and pokeweed mitogen were decreased in the culture of the peripheral blood lymphocytes (PBL) in the 5 HAM patients before the treatment, the stimulation indexes to these mitogens were significantly increased except in 1 case after the IFN-alpha treatment. These changes were based primarily on the depression of the spontaneous proliferation of PBL without mitogen. These results appear to point out a very important phenomenon for the investigation of the pathogenesis of HAM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Concanavalin A / pharmacology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Interferon Type I / pharmacology*
  • Lymphocyte Activation / drug effects
  • Male
  • Middle Aged
  • Paraparesis, Tropical Spastic / drug therapy*
  • Paraparesis, Tropical Spastic / immunology
  • Phytohemagglutinins / pharmacology
  • Pokeweed Mitogens / pharmacology

Substances

  • Interferon Type I
  • Phytohemagglutinins
  • Pokeweed Mitogens
  • Concanavalin A